ImmunoBrain Checkpoint
PrivateLast Round
Grant
Aug 27, 2021
Total Funding Raised
$6.5M
Company Overview
ImmunoBrain Checkpoint is a biopharmaceutical company that develops disease-modifying immunotherapies for neurodegenerative diseases by targeting immune checkpoint pathways.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoBrain Checkpoint Comparables
Compare ImmunoBrain Checkpoint with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alector | 78% | |
| Alzinova | 77% | |
| INmune Bio Inc | 77% | |
ImmunoBrain Checkpoint Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 27, 2021 | ||||
| Series A | Oct 12, 2020 | ||||
| Grant | Sep 1, 2020 | ||||
| Grant | Apr 22, 2020 | ||||
| Strategic | Jun 6, 2017 | ||||
Seed | Feb 1, 2015 |
Key People
Founding team and executive leadership
ImmunoBrain Checkpoint Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The ALS Association | Grant |
| NIH RADx | Grant |
| National Institute on Aging | Grant |
| Yeda Research and Development Company Ltd. | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2021
$5M grant from National Institute on Aging and NIH RADx.
- Sep 1, 2020
$1M grant received from Alzheimer's Association.
ImmunoBrain Checkpoint Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ImmunoBrain Checkpoint's valuation, stock price, and market status.